Nivolumab treatment beyond investigator-assessed progression: Outcomes in patients with relapsed/refractory classical Hodgkin lymphoma from the phase 2 CheckMate 205 study Meeting Abstract
| Authors: | Cohen, J. B.; Engert, A.; Ansell, S. M.; Younes, A.; Trneny, M.; Savage, K. J.; Ramchandren, R.; Collins, G.; Fanale, M. A.; Armand, P.; Zinzani, P. L.; De Boer, J. P.; Shipp, M. A.; Santoro, A.; Timmerman, J. M.; Sacchi, M.; Sy, O.; Kuruvilla, J. |
| Abstract Title: | Nivolumab treatment beyond investigator-assessed progression: Outcomes in patients with relapsed/refractory classical Hodgkin lymphoma from the phase 2 CheckMate 205 study |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419401297 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.650.650 |
| Notes: | Meeting Abstract: 650 -- Source: Wos |
